Trial of Minocycline to Treat Children With Fragile X Syndrome
Completed · Not applicable · Has a placebo group
Conditions studied: Fragile X Syndrome
In brief
This is a single center study at the UC Davis MIND Institute in patients age 3.5-16 years of age with fragile X syndrome (FXS), funded by a National Fragile X Foundation Grant. It is a controlled trial of minocycline, an antibiotic commonly used in children for infection or for treatment of neurodegenerative disorders. We are investigating its use in FXS because it lowers matrix metalloproteinase 9 (MMP9) levels, which are high in FXS, and it also strengthens brain connections in the animal models of FXS. We hypothesize that minocycline will likely be helpful for language, behavior and/or cognition in fragile X patients.
Key facts
- Study ID
- NCT01053156
- Run by
- University of California, Davis
- People needed
- 66
- Starts
- 2010-01-01
- Expected to finish
- 2011-12-01
- Last updated by the study team
- 2017-05-30
Who can join
Age: 4 and older, up to 16. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Must have fragile X syndrome with molecular documentation
- Current pharmacological treatment regimen has been stable for at least 4 weeks
You may not qualify if…
- Subjects who plan to initiate or change pharmacologic or non-pharmacologic interventions during the course of the study
- subjects who are unable to take oral medication
- subjects who have been on minocycline previously
- subjects who are allergic to minocycline or tetracyclines
- subjects who are pregnant
- subjects with history of lupus or hepatic dysfunction
Where it is running
- M.I.N.D. Institute at University of California at Davis Medical Center — Sacramento, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.